Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses
Background & Aims Hepatic markers are utilized in many classification systems of patients with hepatocellular carcinoma and, by measuring organ damage and tumor stage, can influence treatment. Moreover, elevated serum concentrations of aminotransferases and alpha-fetoprotein are indicators of po...
Gespeichert in:
| Veröffentlicht in: | Journal of hepatology 2012-05, Vol.56 (5), p.1080-1088 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1088 |
|---|---|
| container_issue | 5 |
| container_start_page | 1080 |
| container_title | Journal of hepatology |
| container_volume | 56 |
| creator | Raoul, Jean-Luc Bruix, Jordi Greten, Tim F Sherman, Morris Mazzaferro, Vincenzo Hilgard, Philip Scherubl, Hans Scheulen, Max E Germanidis, Georgios Dominguez, Sophie Ricci, Sergio Nadel, Andrea Moscovici, Marius Voliotis, Dimitris Llovet, Josep M |
| description | Background & Aims Hepatic markers are utilized in many classification systems of patients with hepatocellular carcinoma and, by measuring organ damage and tumor stage, can influence treatment. Moreover, elevated serum concentrations of aminotransferases and alpha-fetoprotein are indicators of poor prognosis in patients with hepatocellular carcinoma. We examined the effects of sorafenib on hepatic markers by performing exploratory subset analyses of the Sorafenib HCC Assessment Randomized Protocol (SHARP) trial in patients categorized by baseline concentrations of alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, and bilirubin; and by evaluating the effects of sorafenib on bilirubin concentrations during treatment. Methods Patients (n = 602) were grouped by baseline concentrations of alanine aminotransferase/aspartate aminotransferase (not significantly elevated, mildly elevated, or moderately elevated), alpha-fetoprotein (normal or elevated), and bilirubin (normal or elevated). Bilirubin was measured at baseline and on day 1 of each cycle. Results Patients with elevated baseline concentrations of alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin had shorter overall survival (OS) than those with normal baseline concentrations, irrespective of treatment group. No notable differences in safety profiles were observed between patients with normal vs. elevated alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin. Median changes from baseline in bilirubin concentration at the last cycle of treatment were +0.17 and +0.19 mg/dl in the sorafenib and placebo groups, respectively. Conclusions These subset analyses suggest that sorafenib is safe and effective for hepatocellular carcinoma, irrespective of baseline alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin concentration and that hepatic function remains stable over the course of sorafenib therapy. |
| doi_str_mv | 10.1016/j.jhep.2011.12.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1002561278</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0168827812000475</els_id><sourcerecordid>1002561278</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-577acdd5d10032dd52f1d9a9266c2f9b7a572e1d31a09b3d485a98403b04eda23</originalsourceid><addsrcrecordid>eNp9kk2LFDEQhoMo7rj6BzxILoIHu03S3yLCsqgrLCi7eg7ppJpN25PMprpXBvzxVjujggdPSchTb5InxdhTKXIpZP1qzMcb2OVKSJlLlQvR3WMbWQuRibqU99mGoDZrVdOesEeIoxCiEF35kJ0opcqq7eoN-3EFk5l9DHjjd7yH-TtA4L1BmHwATvm0aznOZl6Qm-B4XGYbt_Dy1wKGAezM48AxJjNA8D2PgU_-DhIflmDX6Nf8-uLs6jOfkzcTx6U3wUx7BHzMHgxmQnhyHE_Z1_fvvpxfZJefPnw8P7vMbCWaOauaxljnKifpAYomapCuM52qa6uGrm9M1SiQrpBGdH3hyrYyXVuKohclOKOKU_bikLtL8XYBnPXWo4VpMgHigppyVVVLEkWoOqA2RcQEg94lvzVpT5BeretRr9b1al1Lpck6FT075i_9Ftyfkt-aCXh-BAxaMw3JBOvxL1c1bddVJXFvDhyQjTsPSaP1ECw4n8izdtH__x5v_ym39IueTvwGe8AxLonM03s1UoG-XvtjbQ-pqDXKpip-AnMBtjI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1002561278</pqid></control><display><type>article</type><title>Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Raoul, Jean-Luc ; Bruix, Jordi ; Greten, Tim F ; Sherman, Morris ; Mazzaferro, Vincenzo ; Hilgard, Philip ; Scherubl, Hans ; Scheulen, Max E ; Germanidis, Georgios ; Dominguez, Sophie ; Ricci, Sergio ; Nadel, Andrea ; Moscovici, Marius ; Voliotis, Dimitris ; Llovet, Josep M</creator><creatorcontrib>Raoul, Jean-Luc ; Bruix, Jordi ; Greten, Tim F ; Sherman, Morris ; Mazzaferro, Vincenzo ; Hilgard, Philip ; Scherubl, Hans ; Scheulen, Max E ; Germanidis, Georgios ; Dominguez, Sophie ; Ricci, Sergio ; Nadel, Andrea ; Moscovici, Marius ; Voliotis, Dimitris ; Llovet, Josep M</creatorcontrib><description>Background & Aims Hepatic markers are utilized in many classification systems of patients with hepatocellular carcinoma and, by measuring organ damage and tumor stage, can influence treatment. Moreover, elevated serum concentrations of aminotransferases and alpha-fetoprotein are indicators of poor prognosis in patients with hepatocellular carcinoma. We examined the effects of sorafenib on hepatic markers by performing exploratory subset analyses of the Sorafenib HCC Assessment Randomized Protocol (SHARP) trial in patients categorized by baseline concentrations of alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, and bilirubin; and by evaluating the effects of sorafenib on bilirubin concentrations during treatment. Methods Patients (n = 602) were grouped by baseline concentrations of alanine aminotransferase/aspartate aminotransferase (not significantly elevated, mildly elevated, or moderately elevated), alpha-fetoprotein (normal or elevated), and bilirubin (normal or elevated). Bilirubin was measured at baseline and on day 1 of each cycle. Results Patients with elevated baseline concentrations of alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin had shorter overall survival (OS) than those with normal baseline concentrations, irrespective of treatment group. No notable differences in safety profiles were observed between patients with normal vs. elevated alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin. Median changes from baseline in bilirubin concentration at the last cycle of treatment were +0.17 and +0.19 mg/dl in the sorafenib and placebo groups, respectively. Conclusions These subset analyses suggest that sorafenib is safe and effective for hepatocellular carcinoma, irrespective of baseline alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin concentration and that hepatic function remains stable over the course of sorafenib therapy.</description><identifier>ISSN: 0168-8278</identifier><identifier>EISSN: 1600-0641</identifier><identifier>DOI: 10.1016/j.jhep.2011.12.009</identifier><identifier>PMID: 22245896</identifier><identifier>CODEN: JOHEEC</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Alanine aminotransferase ; Alanine Transaminase - blood ; Alpha-fetoprotein ; alpha-Fetoproteins - metabolism ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Aspartate aminotransferase ; Aspartate Aminotransferases - blood ; Benzenesulfonates - adverse effects ; Benzenesulfonates - pharmacology ; Benzenesulfonates - therapeutic use ; Bilirubin ; Bilirubin - blood ; Biological and medical sciences ; Biomarkers - blood ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - mortality ; Female ; Gastroenterology and Hepatology ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatic markers ; Humans ; Liver - drug effects ; Liver - metabolism ; Liver - physiopathology ; Liver Neoplasms - drug therapy ; Liver Neoplasms - mortality ; Male ; Medical sciences ; Middle Aged ; Niacinamide - analogs & derivatives ; Phenylurea Compounds ; Prognosis ; Pyridines - adverse effects ; Pyridines - pharmacology ; Pyridines - therapeutic use ; Sorafenib ; Survival Rate ; Treatment Outcome</subject><ispartof>Journal of hepatology, 2012-05, Vol.56 (5), p.1080-1088</ispartof><rights>European Association for the Study of the Liver</rights><rights>2012 European Association for the Study of the Liver</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-577acdd5d10032dd52f1d9a9266c2f9b7a572e1d31a09b3d485a98403b04eda23</citedby><cites>FETCH-LOGICAL-c507t-577acdd5d10032dd52f1d9a9266c2f9b7a572e1d31a09b3d485a98403b04eda23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168827812000475$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25789954$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22245896$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raoul, Jean-Luc</creatorcontrib><creatorcontrib>Bruix, Jordi</creatorcontrib><creatorcontrib>Greten, Tim F</creatorcontrib><creatorcontrib>Sherman, Morris</creatorcontrib><creatorcontrib>Mazzaferro, Vincenzo</creatorcontrib><creatorcontrib>Hilgard, Philip</creatorcontrib><creatorcontrib>Scherubl, Hans</creatorcontrib><creatorcontrib>Scheulen, Max E</creatorcontrib><creatorcontrib>Germanidis, Georgios</creatorcontrib><creatorcontrib>Dominguez, Sophie</creatorcontrib><creatorcontrib>Ricci, Sergio</creatorcontrib><creatorcontrib>Nadel, Andrea</creatorcontrib><creatorcontrib>Moscovici, Marius</creatorcontrib><creatorcontrib>Voliotis, Dimitris</creatorcontrib><creatorcontrib>Llovet, Josep M</creatorcontrib><title>Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses</title><title>Journal of hepatology</title><addtitle>J Hepatol</addtitle><description>Background & Aims Hepatic markers are utilized in many classification systems of patients with hepatocellular carcinoma and, by measuring organ damage and tumor stage, can influence treatment. Moreover, elevated serum concentrations of aminotransferases and alpha-fetoprotein are indicators of poor prognosis in patients with hepatocellular carcinoma. We examined the effects of sorafenib on hepatic markers by performing exploratory subset analyses of the Sorafenib HCC Assessment Randomized Protocol (SHARP) trial in patients categorized by baseline concentrations of alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, and bilirubin; and by evaluating the effects of sorafenib on bilirubin concentrations during treatment. Methods Patients (n = 602) were grouped by baseline concentrations of alanine aminotransferase/aspartate aminotransferase (not significantly elevated, mildly elevated, or moderately elevated), alpha-fetoprotein (normal or elevated), and bilirubin (normal or elevated). Bilirubin was measured at baseline and on day 1 of each cycle. Results Patients with elevated baseline concentrations of alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin had shorter overall survival (OS) than those with normal baseline concentrations, irrespective of treatment group. No notable differences in safety profiles were observed between patients with normal vs. elevated alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin. Median changes from baseline in bilirubin concentration at the last cycle of treatment were +0.17 and +0.19 mg/dl in the sorafenib and placebo groups, respectively. Conclusions These subset analyses suggest that sorafenib is safe and effective for hepatocellular carcinoma, irrespective of baseline alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin concentration and that hepatic function remains stable over the course of sorafenib therapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alanine aminotransferase</subject><subject>Alanine Transaminase - blood</subject><subject>Alpha-fetoprotein</subject><subject>alpha-Fetoproteins - metabolism</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Aspartate aminotransferase</subject><subject>Aspartate Aminotransferases - blood</subject><subject>Benzenesulfonates - adverse effects</subject><subject>Benzenesulfonates - pharmacology</subject><subject>Benzenesulfonates - therapeutic use</subject><subject>Bilirubin</subject><subject>Bilirubin - blood</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Female</subject><subject>Gastroenterology and Hepatology</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepatic markers</subject><subject>Humans</subject><subject>Liver - drug effects</subject><subject>Liver - metabolism</subject><subject>Liver - physiopathology</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - mortality</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Niacinamide - analogs & derivatives</subject><subject>Phenylurea Compounds</subject><subject>Prognosis</subject><subject>Pyridines - adverse effects</subject><subject>Pyridines - pharmacology</subject><subject>Pyridines - therapeutic use</subject><subject>Sorafenib</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>0168-8278</issn><issn>1600-0641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kk2LFDEQhoMo7rj6BzxILoIHu03S3yLCsqgrLCi7eg7ppJpN25PMprpXBvzxVjujggdPSchTb5InxdhTKXIpZP1qzMcb2OVKSJlLlQvR3WMbWQuRibqU99mGoDZrVdOesEeIoxCiEF35kJ0opcqq7eoN-3EFk5l9DHjjd7yH-TtA4L1BmHwATvm0aznOZl6Qm-B4XGYbt_Dy1wKGAezM48AxJjNA8D2PgU_-DhIflmDX6Nf8-uLs6jOfkzcTx6U3wUx7BHzMHgxmQnhyHE_Z1_fvvpxfZJefPnw8P7vMbCWaOauaxljnKifpAYomapCuM52qa6uGrm9M1SiQrpBGdH3hyrYyXVuKohclOKOKU_bikLtL8XYBnPXWo4VpMgHigppyVVVLEkWoOqA2RcQEg94lvzVpT5BeretRr9b1al1Lpck6FT075i_9Ftyfkt-aCXh-BAxaMw3JBOvxL1c1bddVJXFvDhyQjTsPSaP1ECw4n8izdtH__x5v_ym39IueTvwGe8AxLonM03s1UoG-XvtjbQ-pqDXKpip-AnMBtjI</recordid><startdate>201205</startdate><enddate>201205</enddate><creator>Raoul, Jean-Luc</creator><creator>Bruix, Jordi</creator><creator>Greten, Tim F</creator><creator>Sherman, Morris</creator><creator>Mazzaferro, Vincenzo</creator><creator>Hilgard, Philip</creator><creator>Scherubl, Hans</creator><creator>Scheulen, Max E</creator><creator>Germanidis, Georgios</creator><creator>Dominguez, Sophie</creator><creator>Ricci, Sergio</creator><creator>Nadel, Andrea</creator><creator>Moscovici, Marius</creator><creator>Voliotis, Dimitris</creator><creator>Llovet, Josep M</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201205</creationdate><title>Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses</title><author>Raoul, Jean-Luc ; Bruix, Jordi ; Greten, Tim F ; Sherman, Morris ; Mazzaferro, Vincenzo ; Hilgard, Philip ; Scherubl, Hans ; Scheulen, Max E ; Germanidis, Georgios ; Dominguez, Sophie ; Ricci, Sergio ; Nadel, Andrea ; Moscovici, Marius ; Voliotis, Dimitris ; Llovet, Josep M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-577acdd5d10032dd52f1d9a9266c2f9b7a572e1d31a09b3d485a98403b04eda23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alanine aminotransferase</topic><topic>Alanine Transaminase - blood</topic><topic>Alpha-fetoprotein</topic><topic>alpha-Fetoproteins - metabolism</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Aspartate aminotransferase</topic><topic>Aspartate Aminotransferases - blood</topic><topic>Benzenesulfonates - adverse effects</topic><topic>Benzenesulfonates - pharmacology</topic><topic>Benzenesulfonates - therapeutic use</topic><topic>Bilirubin</topic><topic>Bilirubin - blood</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Female</topic><topic>Gastroenterology and Hepatology</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepatic markers</topic><topic>Humans</topic><topic>Liver - drug effects</topic><topic>Liver - metabolism</topic><topic>Liver - physiopathology</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - mortality</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Niacinamide - analogs & derivatives</topic><topic>Phenylurea Compounds</topic><topic>Prognosis</topic><topic>Pyridines - adverse effects</topic><topic>Pyridines - pharmacology</topic><topic>Pyridines - therapeutic use</topic><topic>Sorafenib</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raoul, Jean-Luc</creatorcontrib><creatorcontrib>Bruix, Jordi</creatorcontrib><creatorcontrib>Greten, Tim F</creatorcontrib><creatorcontrib>Sherman, Morris</creatorcontrib><creatorcontrib>Mazzaferro, Vincenzo</creatorcontrib><creatorcontrib>Hilgard, Philip</creatorcontrib><creatorcontrib>Scherubl, Hans</creatorcontrib><creatorcontrib>Scheulen, Max E</creatorcontrib><creatorcontrib>Germanidis, Georgios</creatorcontrib><creatorcontrib>Dominguez, Sophie</creatorcontrib><creatorcontrib>Ricci, Sergio</creatorcontrib><creatorcontrib>Nadel, Andrea</creatorcontrib><creatorcontrib>Moscovici, Marius</creatorcontrib><creatorcontrib>Voliotis, Dimitris</creatorcontrib><creatorcontrib>Llovet, Josep M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raoul, Jean-Luc</au><au>Bruix, Jordi</au><au>Greten, Tim F</au><au>Sherman, Morris</au><au>Mazzaferro, Vincenzo</au><au>Hilgard, Philip</au><au>Scherubl, Hans</au><au>Scheulen, Max E</au><au>Germanidis, Georgios</au><au>Dominguez, Sophie</au><au>Ricci, Sergio</au><au>Nadel, Andrea</au><au>Moscovici, Marius</au><au>Voliotis, Dimitris</au><au>Llovet, Josep M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses</atitle><jtitle>Journal of hepatology</jtitle><addtitle>J Hepatol</addtitle><date>2012-05</date><risdate>2012</risdate><volume>56</volume><issue>5</issue><spage>1080</spage><epage>1088</epage><pages>1080-1088</pages><issn>0168-8278</issn><eissn>1600-0641</eissn><coden>JOHEEC</coden><abstract>Background & Aims Hepatic markers are utilized in many classification systems of patients with hepatocellular carcinoma and, by measuring organ damage and tumor stage, can influence treatment. Moreover, elevated serum concentrations of aminotransferases and alpha-fetoprotein are indicators of poor prognosis in patients with hepatocellular carcinoma. We examined the effects of sorafenib on hepatic markers by performing exploratory subset analyses of the Sorafenib HCC Assessment Randomized Protocol (SHARP) trial in patients categorized by baseline concentrations of alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, and bilirubin; and by evaluating the effects of sorafenib on bilirubin concentrations during treatment. Methods Patients (n = 602) were grouped by baseline concentrations of alanine aminotransferase/aspartate aminotransferase (not significantly elevated, mildly elevated, or moderately elevated), alpha-fetoprotein (normal or elevated), and bilirubin (normal or elevated). Bilirubin was measured at baseline and on day 1 of each cycle. Results Patients with elevated baseline concentrations of alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin had shorter overall survival (OS) than those with normal baseline concentrations, irrespective of treatment group. No notable differences in safety profiles were observed between patients with normal vs. elevated alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin. Median changes from baseline in bilirubin concentration at the last cycle of treatment were +0.17 and +0.19 mg/dl in the sorafenib and placebo groups, respectively. Conclusions These subset analyses suggest that sorafenib is safe and effective for hepatocellular carcinoma, irrespective of baseline alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin concentration and that hepatic function remains stable over the course of sorafenib therapy.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>22245896</pmid><doi>10.1016/j.jhep.2011.12.009</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8278 |
| ispartof | Journal of hepatology, 2012-05, Vol.56 (5), p.1080-1088 |
| issn | 0168-8278 1600-0641 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1002561278 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Aged Aged, 80 and over Alanine aminotransferase Alanine Transaminase - blood Alpha-fetoprotein alpha-Fetoproteins - metabolism Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Aspartate aminotransferase Aspartate Aminotransferases - blood Benzenesulfonates - adverse effects Benzenesulfonates - pharmacology Benzenesulfonates - therapeutic use Bilirubin Bilirubin - blood Biological and medical sciences Biomarkers - blood Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - mortality Female Gastroenterology and Hepatology Gastroenterology. Liver. Pancreas. Abdomen Hepatic markers Humans Liver - drug effects Liver - metabolism Liver - physiopathology Liver Neoplasms - drug therapy Liver Neoplasms - mortality Male Medical sciences Middle Aged Niacinamide - analogs & derivatives Phenylurea Compounds Prognosis Pyridines - adverse effects Pyridines - pharmacology Pyridines - therapeutic use Sorafenib Survival Rate Treatment Outcome |
| title | Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T07%3A11%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relationship%20between%20baseline%20hepatic%20status%20and%20outcome,%20and%20effect%20of%20sorafenib%20on%20liver%20function:%20SHARP%20trial%20subanalyses&rft.jtitle=Journal%20of%20hepatology&rft.au=Raoul,%20Jean-Luc&rft.date=2012-05&rft.volume=56&rft.issue=5&rft.spage=1080&rft.epage=1088&rft.pages=1080-1088&rft.issn=0168-8278&rft.eissn=1600-0641&rft.coden=JOHEEC&rft_id=info:doi/10.1016/j.jhep.2011.12.009&rft_dat=%3Cproquest_cross%3E1002561278%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1002561278&rft_id=info:pmid/22245896&rft_els_id=1_s2_0_S0168827812000475&rfr_iscdi=true |